Why is coronavirus a good biological weapon (bioweapon)?
Why is the covid-19 vaccine the ultimate endgame?
Part I of a multi-part PPT on the dangers of covid-19 vaccine.
3. WHAT MAKES FOR AN EFFECTIVE BIO-
WEAPON?
1. Preparation/Weaponization: Easy dispersal and facilitates storage while
easy to maintain in lab with relatively low cost
2. Dispersal: The challenge of biological weapons; airborne transmission
least challenging
3. Persistence: Should be able to survive long enough to find suitable host
and deal damage
4. Incubation Time: If the weapon kills too quickly, the host will not be able
to infect others
5. High-Containment Laboratories: Biosafety (BSL) lvl 1, 2 organisms are
safe to experiment on; BSL 3, 4 are for possible aerosolized or easily
transmissible microbes
5. SARS-COV-2
FAMILY TREE
Hu, B., Guo, H., Zhou, P. et
al. Characteristics of SARS-
CoV-2 and COVID-19. Nat
Rev Microbiol 19, 141–154
(2021).
https://doi.org/10.1038/s4
1579-020-00459-7
6. GENERAL SARS-COV-2 INFORMATION
• Positive-sense single strand RNA virus (+ssRNA)
• Other positive-sense single strand RNA viruses include
Hepacivirus C, West Nile Virus, and Dengue Fever Virus
• Shares 75% genome with SARS-CoV; shares 50% with MERS-CoV
• Contains club-shaped spikes that project from surface similar
to Solar Corona, therefore granting their name
• Transmission can be aerosol, fomite, or fecal-oral
7. WHY CHOOSE CORONAVIRIDAE?
1. Preparation/Weaponization: Cheap and Easy: Frequency of human
coronaviridae virus infection per person was 1x every 8 months. Look at
the family tree. There are TONS of variants!
2. Dispersal: Transmission via aerosol, fomite, or fecal-oral.
3. Persistence: Can remain viable on surfaces for days.
4. Incubation Time: Per CDC, anywhere from 2-14 days
5. High-Containment Laboratories: Funding is an issue this PPT does not
aim to address.
Clark, D. P., & Pazdernik, N. J. (2016). Biological Warfare: Infectious Disease and Bioterrorism. Biotechnology, 687–
719. https://doi.org/10.1016/B978-0-12-385015-7.00022-3
Macnaughton M. R. (1982). Occurrence and frequency of coronavirus infections in humans as determined by enzyme-
linked immunosorbent assay. Infection and immunity, 38(2), 419–423. https://doi.org/10.1128/IAI.38.2.419-
423.1982
Aerosol and surface stability of HCoV-19 (SARS-CoV-2) compared to SARS-CoV-1. van Doremalen N, Bushmaker T,
8. WHY IS COVID-19
VACCINE THE
ENDGAME WEAPON?
WHY IS IT NOT SARS-
COV-2 ITSELF?
Simply put: if SARS-Cov-2 was
the endgame weapon, it does
not deal enough death or
disease to be effective en
masse.
9.
10. WHY SARS-COV-2 FAILS AS A WEAPON BY
ITSELF
• During infection, as shown by previous 2 slides, death rate
hovers under 10% for nearly all age ranges
• Post infection, as shown through MULTIPLE studies conducted
by scientists world wide including UCLA and UAB, antibodies
relating to SARS-CoV-2 rapidly declines within 3 months
• SARS-CoV-2 was NEVER going to be deadly enough as a
biological weapon, but its abundance in the wild, ease of
transmission, persistence of viability, as well as a high
incubation time makes it a great candidate for biowarfare.
Ibarrondo, F. J., Fulcher, J. A., Goodman-Meza, D., Elliott, J., Hofmann, C., Hausner, M. A., Ferbas, K. G., Tobin, N. H.,
Aldrovandi, G. M., & Yang, O. O. (2020). Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19.
New England Journal of Medicine, 383(11), 1085–1087. https://doi.org/10.1056/nejmc2025179
11. WHY CORONAVIRIDAE VACCINE?
VACCINE-ASSOCIATED DISEASE
ENHANCEMENT (VADE)
• Simply put: If a person was infected once, recovered, the next
time s/he was infected, s/he would experience an enhanced
infection.
• When a vaccine is involved, this is called Vaccine-Associated
Disease Enhancement (VADE)
• As a part of Positive-sense Single-strand RNA Virus family,
corona shares this characteristic with its fellow viruses: RSV and
Dengue
13. WHY CORONAVIRIDAE VACCINE?
VACCINE-ASSOCIATED DISEASE
ENHANCEMENT (VADE)
HOW IMPORTANT IS VADE?
• Dengue Fever Vaccine as an Example:
• “An increased incidence of severe dengue was observed in vaccinated
children aged 2 to 5 years, and in vaccinated children who had not previously
been infected with one of the dengue viruses.”
• “Because of the excess risk of hospitalized dengue identified among
seronegative trial participants who became infected after vaccination, the
WHO Global Advisory Committee on Vaccine Safety (GACVS) concluded that
individuals who have not been infected with wild dengue virus, i.e. who are
seronegative, should not be vaccinated with CYD-TDV.”
• In conclusion: With another +ssRNA virus with similar concerns of Antibody-
Dependent Enhancement/Vaccine-Associated Disease Enhancement, vaccines
can compound the issue, not resolve it. WHO came to the same conclusion.
"Dengue vaccine (Dengvaxia°). Not for large-scale use". english.prescrire.org. 39 (433): 810. November 2019.
"Dengue vaccine: WHO position paper – September 2018" (PDF). Weekly Epidemiological Record. 36 (93): 457–76. 7 September 2018.
14. WHY CORONAVIRIDAE VACCINE?
VACCINE-ASSOCIATED DISEASE
ENHANCEMENT (VADE)
HOW IMPORTANT IS VADE?
• It is established that natural coronavirus was never going to do mass
damage as a bioweapon … but with a vaccine that can potentially
enhance the effects of Covid through the body’s own immune system
failures, sudden SARS-CoV-2 is now viable as a bioweapon candidate.
Except there is one stipulation: there has to be mass vaccinations.
• An important point for later PPTs: the engineered spike protein CAN
cause damage. To make it a long term infectant would mean to somehow
enforce it into the DNA. Wonder why this vaccine is mRNA and not a
bunch of preformed spike proteins? Stay tuned.
• Points of discussion in relation to ADE/VADE in future Covid-19 Vaccine
PPTs:
1. Original antigenic sin
